Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $10.14 Consensus Price Target from Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been assigned a consensus rating of “Hold” from the nine ratings firms that are covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $10.14.

Several analysts recently issued reports on NMRA shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $5.00 price target on shares of Neumora Therapeutics in a report on Tuesday, March 4th. HC Wainwright dropped their target price on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. Bank of America dropped their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Guggenheim cut shares of Neumora Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, March 7th. Finally, Stifel Nicolaus lowered shares of Neumora Therapeutics from a “buy” rating to a “hold” rating and lowered their price target for the stock from $6.00 to $2.00 in a research report on Friday, March 7th.

Neumora Therapeutics Trading Down 4.9 %

Shares of NMRA stock opened at $1.16 on Tuesday. The company has a market capitalization of $187.90 million, a PE ratio of -0.62 and a beta of 2.59. The firm has a fifty day simple moving average of $1.75 and a 200-day simple moving average of $7.99. Neumora Therapeutics has a twelve month low of $1.13 and a twelve month high of $17.19.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.09. Equities research analysts predict that Neumora Therapeutics will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Neumora Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in shares of Neumora Therapeutics by 54.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock valued at $26,159,000 after purchasing an additional 694,385 shares in the last quarter. Barclays PLC lifted its stake in Neumora Therapeutics by 352.9% during the third quarter. Barclays PLC now owns 129,210 shares of the company’s stock valued at $1,708,000 after buying an additional 100,678 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Neumora Therapeutics by 139.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock worth $9,224,000 after purchasing an additional 406,891 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Neumora Therapeutics in the third quarter worth approximately $1,097,000. Finally, Wexford Capital LP lifted its position in shares of Neumora Therapeutics by 90.1% in the third quarter. Wexford Capital LP now owns 217,879 shares of the company’s stock worth $2,878,000 after purchasing an additional 103,285 shares in the last quarter. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.